News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

STB Lifesaving Technologies: Successful Pre-IND FDA Filing for STB's FAST(R) Dressing Propels Lifesaving Technology Forward


10/18/2010 9:13:03 AM

ROCKVILLE, Md., Oct. 18 /PRNewswire/ -- STB Lifesaving Technologies® today announced that is has completed a successful pre-Investigational New Drug (pre-IND) submission to the U.S. Food and Drug Administration (FDA) for its lead product, the Fibrin Adhesive STat®, or (FAST®) dressing.

STB® has conducted successful animal studies for the FAST® dressing with both military and commercial partners and is further supported by published data from the American Red Cross. In these published comparative animal studies, Fibrin Adhesive STat®, or (FAST®) dressing has proven to be functionally superior in significantly reducing blood loss. The FAST® dressing contains large quantities of the human blood clotting proteins fibrinogen, thrombin, and Factor XIII in a dry form. Once in contact with the wound, the components in the FAST® dressing are instantly activated to form a fibrin clot similar to that which results from the body's own clotting process.

"The FDA provided us with some very helpful and substantive comments," said Richard Moscarello, CEO of STB®. "We have incorporated them and now are finalizing our development plan and partner relationships, so we can go forward with our IND filing as soon as possible. This will a very significant milestone in the strategic plan we've set for STB®, and will allow us to penetrate the multi-billion dollar hemostatic market and begin saving lives." The Company has the remaining pre-IND development work and animal studies for the FAST® dressing underway.

STB Lifesaving Technologies® is a biotechnology company that is developing a comprehensive suite of products to stop serious and life threatening bleeding in trauma and surgical settings. Its flagship product, Fibrin Adhesive STat (FAST®) dressing, is designed to be effective against the full spectrum of blood loss, including severe arterial and venous bleeding.

SOURCE STB Lifesaving Technologies


Read at BioSpace.com

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES